FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

30 letters match. Newest first.

  1. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  2. Huons Co., Ltd.

    FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.

    High risk
  3. Erkul Kozmetik Sanayi ve Ticaret A.S.

    Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.

    High risk
  4. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  5. Novo Nordisk Inc.

    FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.

    High risk
  6. cheaptrustedpharmacy.com

    cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.

    High risk
  7. Miach Orthopaedics

    FDA warns Miach Orthopaedics over quality-system failures in manufacturing its BEAR ACL Implant, including sterility monitoring and nonconforming product controls.

    High risk
  8. Rex Implants Inc.

    Rex Implants warned for unapproved dental implant devices and uncleared changes to its cleared implant system.

    High risk
  9. Red Oak Instruments, LLC

    Red Oak Instruments marketed RU-Fit dynamometer for concussion screening without FDA clearance and had MDR and quality system violations.

    High risk
  10. Shree Jaya Laboratories PVT. LTD.

    FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.

    High risk
  11. Sanofi

    FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.

    High risk
  12. Adept Medical Ltd.

    Adept Medical Ltd. warning letter cites quality system and premarket violations for NeoZoline ventilation tubes, including unvalidated sterilization.

    High risk
  13. Rolence Ent. Inc.

    FDA warns Rolence Ent. Inc. over quality system and MDR failures for its XR-01 Portable X-ray System.

    High risk
  14. Namita A. Goyal, M.D.

    FDA warned clinical investigator Dr. Namita Goyal over a biologic trial that enrolled ineligible subjects and kept poor records.

    High risk
  15. Augustine Temperature Management, LLC

    FDA warns Augustine Temperature Management over patient warming devices after unreported burn and quality failures.

    High risk
  16. Future Diagnostics Solutions B.V.

    FDA cites Future Diagnostics over quality-system and reporting failures for STAT IntraOperative Intact PTH immunoassay kits.

    High risk
  17. Medline Industries, LP

    FDA warns Medline over uncleared syringes in surgical kits and unresolved design and complaint failures.

    High risk
  18. www.directpharmashop.net

    FDA warned DirectPharmaShop.net over selling unapproved, misbranded antipsychotics to U.S. consumers online.

    High risk
  19. Lex Inc.

    FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.

    High risk
  20. K.C. Pharmaceuticals Inc.

    FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.

    High risk
  21. Intas Pharmaceuticals Limited

    FDA warned Intas Pharmaceuticals about serious manufacturing-quality violations, including data integrity failures and inaccurate environmental monitoring, at its India drug plant.

    High risk
  22. Outset Medical, Inc.

    FDA warns Outset Medical over unapproved TabloCart and promotion of Tablo dialysis system for unapproved CRRT use.

    High risk
  23. ElectRx and Health Solutions, LLC

    ElectRx causes introduction of unapproved and misbranded prescription drugs into interstate commerce by substituting foreign-sourced drugs for FDA-approved prescriptions.

    High risk
  24. Olympus Medical Systems Corporation

    Olympus Medical Systems failed to submit timely Medical Device Reports for endoscope malfunctions, FDA says.

    High risk
  25. Aizu Olympus Co., Ltd.

    Aizu Olympus failed to validate endoscope designs and manufacturing processes and lacked MDR procedures, FDA says.

    High risk
  26. Lupin Limited

    FDA warned Lupin Limited of current good manufacturing practice (CGMP) violations at its Tarapur API plant involving cleaning and genotoxic impurity controls.

    High risk
  27. Cetylite Industries, Inc.

    FDA warned Cetylite Industries over CGMP violations at its Pennsauken, NJ facility, including unvalidated testing and inadequate OOS investigations for topical anesthetics.

    High risk
  28. VitaStik, Inc.

    FDA warned VitaStik that its oral inhalation sticks are unapproved new drugs marketed with claims to treat asthma, anxiety, sleep and other conditions.

    High risk
  29. Marcus Research Laboratory, Inc.

    FDA warned Marcus Research Laboratory after a May 2021 inspection found it released povidone iodine API made after reactor fires and smoke without fully testing for contamination.

    High risk
  30. Missouri Analytical Laboratories Inc

    Missouri Analytical Laboratories, a contract drug testing lab, cited for manufacturing practice violations including inadequate out-of-specification investigations and data integrity failures.

    High risk